BridgeBio

Pfizer's 'entrenched' tafamidis franchise will be tough to challenge for Alnylam, BridgeBio: analysts
Pfizer's 'entrenched' tafamidis franchise will be tough to challenge for Alnylam, BridgeBio: analysts
Fierce Pharma
Pfizer
BridgeBio
Alnylam
FDA
clinical trials
ATTR-CM
physicians
tafamidis
Flag link:
BridgeBio Pharma Shares Rise 14% on Expected Results from Heart-Disease Study
BridgeBio Pharma Shares Rise 14% on Expected Results from Heart-Disease Study
Marketwatch
BridgeBio
transthyretin amyloid cardiomyopathy
Flag link:
Why BridgeBio Pharma Stock Is Plunging Today
Why BridgeBio Pharma Stock Is Plunging Today
Motley Fool
BridgeBio
clinical trials
acoramidis
ATTR-CM
Flag link:
Biopharma stocks go back to bleak
Biopharma stocks go back to bleak
EP Vantage
Albireo Pharma
Amryt Pharma
Apellis Pharmaceuticals
AstraZeneca
BridgeBio
Novo Nordisk
Pfizer
Protagonist Therapeutics
Provention Bio
Reata Pharmaceuticals
Regeneron
Sanofi
Seagen
Flag link:
BioMarin Answers BridgeBio's Challenge with sNDA for Achondroplasia
BioMarin Answers BridgeBio's Challenge with sNDA for Achondroplasia
BioSpace
Biomarin
BridgeBio
achondroplasia
FDA
Voxzogo
Flag link:
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study
Investors Business Daily
BridgeBio
dwarfism
infigratinib
achondroplasia
Flag link:
FDA Review: Phanes, Pfizer, GSK and More
FDA Review: Phanes, Pfizer, GSK and More
BioSpace
FDA
Phanes
Pfizer
GSK
Regeneron
Eagle Pharmaceuticals
Galactin Therapeutics
BridgeBio
Gilead Sciences
Covis Pharma
scPharmaceuticals
XACT Robotics
BioMind Labs
Flag link:
$2.4B BridgeBio/Helsinn Liver Cancer Deal Falls Apart
$2.4B BridgeBio/Helsinn Liver Cancer Deal Falls Apart
BioSpace
BridgeBio
Helsinn
liver cancer
Truseltiq
Flag link:
BridgeBio's CEO on staying alive, 'motherhood and apple pie'
BridgeBio's CEO on staying alive, 'motherhood and apple pie'
Fierce Biotech
BridgeBio
layoffs
Flag link:
When will biotech markets get better? BridgeBio fears they may stay 'pretty bad' until 2024
When will biotech markets get better? BridgeBio fears they may stay 'pretty bad' until 2024
Fierce Biotech
BridgeBio
layoffs
biotech
Flag link:
BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS deal
BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS deal
Fierce Biotech
BridgeBio
priority review vouchers
FDA
Flag link:
A week after disclosing layoffs, BridgeBio nets a $90M upfront cancer R&D pact with Bristol Myers
A week after disclosing layoffs, BridgeBio nets a $90M upfront cancer R&D pact with Bristol Myers
Endpoints
BridgeBio
Bristol Myers Squibb
cancer
R&D
Flag link:
‘Tis the Season: Job Cuts and C-Suite Shifts at Novartis, BridgeBio and Nektar
‘Tis the Season: Job Cuts and C-Suite Shifts at Novartis, BridgeBio and Nektar
BioSpace
Novartis
Nektar
BridgeBio
layoffs
restructuring
executives
Flag link:
BridgeBio says trial for acoramidis in transthyretin amyloidosis did not meet main goal
BridgeBio says trial for acoramidis in transthyretin amyloidosis did not meet main goal
Seeking Alpha
BridgeBio
acoramidis
clinical trials
transthyretin amyloidosis
Flag link:
Bridgebio sets its heart on besting Pfizer
Bridgebio sets its heart on besting Pfizer
EP Vantage
BridgeBio
Pfizer
acoramidis
Vyndaqel
amyloidosis
transthyretin amyloid cardiomyopathy
Flag link:
BridgeBio Gets $750M on Credit to Fuel Long List of Programs
BridgeBio Gets $750M on Credit to Fuel Long List of Programs
Pharma Live
BridgeBio
funding
research and development
Flag link:
Bristol Myers Squibb catches the SHP2 wave in a new collaboration deal with BridgeBio
Bristol Myers Squibb catches the SHP2 wave in a new collaboration deal with BridgeBio
Endpoints
Bristol Myers Squibb
SHP2 inhibitors
Opdivo
BridgeBio
cancer
Flag link:
With early phase 2 data, BridgeBio plots next steps for hypoparathyroidism drug
With early phase 2 data, BridgeBio plots next steps for hypoparathyroidism drug
Fierce Biotech
BridgeBio
hypoparathyroidism
clinical trials
encaleret
Flag link:
BridgeBio spins gold out of an Alexion castoff, scoring an FDA approval in rare metabolism disorder
BridgeBio spins gold out of an Alexion castoff, scoring an FDA approval in rare metabolism disorder
Endpoints
BridgeBio
fosdenopterin
Nulibry
ALXN1101
molybdenum cofactor deficiency type A
FDA
Alexion
Flag link:
BridgeBio grabs a second priority review for the portfolio — giving Perceptive startup cause to celebrate
BridgeBio grabs a second priority review for the portfolio — giving Perceptive startup cause to celebrate
Endpoints
BridgeBio
priority review
QED Therapeutics
Flag link:

Pages